Does Rallies show 13F holders for MGRX?

Yes. Rallies tracks hedge fund and 13F ownership data for MGRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is MGRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MGRX. It does not provide personalized investment advice.

MGRX (Mangoceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Mangoceuticals, Inc. Common Stock (MGRX) is a publicly traded Healthcare sector company. As of May 21, 2026, MGRX trades at $0.40 with a market cap of $6.87M and a P/E ratio of -0.19. MGRX moved +1.62% today. Year to date, MGRX is -48.49%; over the trailing twelve months it is -72.97%. Its 52-week range spans $0.16 to $7.66. Rallies surfaces MGRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns MGRX stock?

Hedge funds tracked by Rallies that own MGRX include Citadel Advisors. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Mangoceuticals, Inc. Common Stock.

MGRX Key Metrics

Key financial metrics for MGRX
Metric	Value
Price	$0.40
Market Cap	$6.87M
P/E Ratio	-0.19
EPS	$-2.17
Dividend Yield	0.00%
52-Week High	$7.66
52-Week Low	$0.16
Volume	69
Avg Volume	0
Revenue (TTM)	$456.02K
Net Income	$-20.64M
Gross Margin	54.91%

Top Hedge Funds Holding MGRX

Citadel Advisors holds 133.19K shares of MGRX, changed +16.43% as of Jun 30, 2024.

Latest MGRX News

Mangoceuticals Seeks Global Patent for MGX-0024 in Over 150 Countries after 29,000-Bird Trial — Mar 6, 2026
Mangoceuticals Sees Zero Respiratory Mortality in 29,000-Bird Trial and 60% H5N1 Death Reduction — Feb 23, 2026
Mangoceuticals Shares Soar 50% After 336% Sales Surge for $99 TRT Program — Feb 20, 2026
MangoRx’s $99 TRT Program Drives 336% Sales Surge, Cuts CAC by 54% — Feb 19, 2026

Recent MGRX Insider Trades

JOHNSTON EUGENE M sold 3.33K (~$3.88K) on Dec 15, 2025.
JOHNSTON EUGENE M sold 5.00K (~$5.97K) on Dec 9, 2025.
JOHNSTON EUGENE M sold 10.00K (~$11.28K) on Dec 5, 2025.

MGRX Analyst Consensus

MGRX analyst coverage data. Average price target: $0.00.

Common questions about MGRX

Who owns MGRX stock?: Hedge funds tracked by Rallies that own MGRX include Citadel Advisors. The latest tracked quarter is Jun 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Mangoceuticals, Inc. Common Stock.
Does Rallies show 13F holders for MGRX?: Yes. Rallies tracks hedge fund and 13F ownership data for MGRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is MGRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MGRX. It does not provide personalized investment advice.